Clinical trial
The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin…
NCT00000961 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00000961 |
|---|---|
| Title | The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants |
| Official title | A Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HIVIG) and of Zidovudine (ZDV) in Infants With Documented HIV Infections |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Abbott Industry Glaxo Wellcome |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Anti-HIV Immune Serum Globulin (Human), Zidovudine |
| Enrollment | 112 |
| Primary completion | May 1, 1991 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 4, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: